FDA Opens Comment Period on GenAI Device Regulation - Medical Device and Diagnostic industry
Reported by Medical Device and Diagnostic industry · all stories from mddionline.com
Editorial digest
The U.S. Food and Drug Administration has opened a period for public comments regarding the regulation of generative artificial intelligence in medical devices.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at Medical Device and Diagnostic industry →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom8/20/2026
FDA weighs regulatory approach for genAI medical devices - MobiHealthNews
The FDA is deliberating its regulatory strategy for generative AI medical devices.
- Reputable trade press8/20/2026
FDA considers ‘competency-based’ evaluations for GenAI-enabled medical devices - MassDevice
The FDA is considering 'competency-based' evaluations for generative AI medical devices.
- Trusted health newsroom9/9/2026
STAT+: ARPA-H to invest $62 million to develop FDA-authorized AI to help treat heart failure
ARPA-H plans to invest $62 million in FDA-authorized AI for heart failure treatment.
- Trusted health newsroom9/3/2026
STAT+: FDA pilot offers generative AI medical devices a path to patients before they are authorized
FDA pilot program allows generative AI devices to reach patients pre-authorization.
- Trusted health newsroom8/19/2026
FDA seeks feedback on generative AI regulations - MedTech Dive
The FDA is soliciting public input on regulating generative AI technologies.
- Trusted health newsroom9/1/2026
STAT+: FDA clears Stryker’s ‘surgical cockpit’ that uses Apple’s VR headset, Vision Pro
Stryker's system for surgery, using Apple Vision Pro, received FDA clearance.